Therapeutics update in immune-mediated rheumatic diseases: rheumatoid arthritis, idiopathic inflammatory myositis and ANCA-associated vasculitis
Zollinger-Read, Caroline Filer, Andrew
Zollinger-Read, Caroline
Filer, Andrew
Affiliation
University of Birmingham; University Hospitals Birmingham NHS Foundation Trust
Other Contributors
Publication date
2025-09-02
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Immune-mediated inflammatory diseases (IMIDs) are a group of common clinically diverse conditions that are characterised by systemic inflammation. They often pose medical challenges due to their multi-organ involvement, chronicity, associated comorbidities and poor impact on quality of life for patients. The management for IMIDs has changed profoundly over the past 20 years, with the paradigm of treatment shifting away from broad immunosuppression towards pathway-specific targeted treatment. This editorial will focus on three immune mediated rheumatic diseases that physicians may encounter in their clinical practice; rheumatoid arthritis (RA), idiopathic inflammatory myositis (IIM) and anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis (AAV). This editorial will provide a concise overview of the current targeted treatment landscape of these three conditions.
Citation
Zollinger-Read C, Filer A. Therapeutics update in immune-mediated rheumatic diseases: Rheumatoid arthritis, idiopathic inflammatory myositis and ANCA-associated vasculitis. Clin Med (Lond). 2025 Sep;25(5):100507. doi: 10.1016/j.clinme.2025.100507. Epub 2025 Sep 2.
Type
Article